Cormedix Inc. 8-K Summary
Business Context and Reporting Period
Cormedix Inc. filed this Form 8-K on May 19, 2014, to report a material event regarding its listing status on the NYSE MKT. The filing addresses compliance issues identified in the Company's Form 10-Q for the quarter ended March 31, 2014.
Key Financial Metrics
The filing references specific financial thresholds that triggered the listing notice:
- Stockholders' Equity: Reported as less than $2 million and $4 million as of March 31, 2014, failing Sections 1003(a)(i) and 1003(a)(ii) of the NYSE MKT Company Guide.
- Net Losses: The Company reported net losses in its four most recent fiscal years ended December 31, 2013.
- Other Metrics: The filing text does not provide specific values for revenue, cash flow, margins, debt, or liquidity beyond the equity and loss indicators.
Material Changes and Listing Status
On May 19, 2014, Cormedix received a notice from the NYSE MKT stating it does not meet continued listing standards. Consequently, the Company is subject to Section 1009 of the Company Guide. If the Company fails to regain compliance or make progress consistent with a required plan, the NYSE MKT will initiate delisting proceedings.
Outlook, Compliance Plan, and Risks
Compliance Plan: Cormedix must submit a plan of compliance to the NYSE MKT no later than June 18, 2014. The plan must detail how the Company intends to regain compliance with equity and profitability standards by December 19, 2014 (the "Plan Period").
Risks: The primary risk is delisting from the NYSE MKT if the Company fails to submit an acceptable plan or fails to make progress during the Plan Period. During the Plan Period, the Company will be subject to periodic review.
Key Facts for Investor Verification
- Verify the specific stockholders' equity balance as of March 31, 2014, in the Form 10-Q.
- Confirm the timeline for the submission of the compliance plan (due June 18, 2014).
- Monitor the NYSE MKT's acceptance of the compliance plan and subsequent progress reports.
- Review the attached press release (Exhibit 99.1) for additional management commentary on the situation.